original ) (raw )In vitro validation of γ γ-secretase inhibitors alone or in combination with other anti-cancer drugs for the treatment of T-cell acute lymphoblastic leukemia
Kim De Keersmaecker
2008
View PDFchevron_right
In vitro validation of gamma-secretase inhibitors alone or in combination with other anti-cancer drugs for the treatment of T-cell acute lymphoblastic leukemia
Kim Keersmaecker
Haematologica
View PDFchevron_right
Complete hematologic response of early T-cell progenitor acute lymphoblastic leukemia to the γ-secretase inhibitor BMS-906024: genetic and epigenetic findings in an outlier case
Daniel Deangelo
Molecular Case Studies, 2015
View PDFchevron_right
Inhibition of NOTCH Signaling by Gamma Secretase Inhibitor Engages the RB Pathway and Elicits Cell Cycle Exit in T-Cell Acute Lymphoblastic Leukemia Cells
SUDHIR RAO
Cancer Research, 2009
View PDFchevron_right
Dual antitumor mechanisms of Notch signaling inhibitor in a T-cell acute lymphoblastic leukemia xenograft model
Shigeo Masuda
Cancer Science, 2009
View PDFchevron_right
γ-secretase inhibitors: Notch so bad
Gerard Grosveld
Nature Medicine, 2009
View PDFchevron_right
Notch signaling as a therapeutic target for acute lymphoblastic leukemia
Diana Bellavia
Expert opinion on therapeutic targets, 2018
View PDFchevron_right
Down-regulation of the Notch pathway mediated by a γ-secretase inhibitor induces anti-tumour effects in mouse models of T-cell leukaemia
Julie Gorenstein
British Journal of Pharmacology, 2009
View PDFchevron_right
Palomero T et al Leukemia 2006
Gopeshwar Narayan
View PDFchevron_right
Regulation of PTEN by CK2 and Notch1 in primary T-cell acute lymphoblastic leukemia: rationale for combined use of CK2-and γ-secretase inhibitors
Joao Barata
2010
View PDFchevron_right
How we treat T-cell acute lymphoblastic leukemia in adults
SiewLian Chong
Blood, 2015
View PDFchevron_right
T-lymphoid/myeloid mixed phenotype acute leukemia and early T-cell precursor lymphoblastic leukemia similarities with NOTCH1 mutation as a good prognostic factor
Carolina Zampier
Cancer Management and Research, 2019
View PDFchevron_right
Blockade of Oncogenic NOTCH1 with the SERCA Inhibitor CAD204520 in T Cell Acute Lymphoblastic Leukemia
Federica Rizzi
Cell Chemical Biology, 2020
View PDFchevron_right
More Insights on the Use of γ-Secretase Inhibitors in Cancer Treatment
José Fernández Piqueras
The Oncologist, 2020
View PDFchevron_right
Significance of NOTCH1 mutations détections in T-acute lymphoblastic leukemia patients
Salah Aref
Cancer Biomarkers, 2020
View PDFchevron_right
Regulation of PTEN by CK2 and Notch1 in primary T-cell acute lymphoblastic leukemia: rationale for combined use of CK2- and -secretase inhibitors
Joao Barata
Haematologica, 2010
View PDFchevron_right
Inhibition of γ‑secretase activity synergistically enhances tumour necrosis factor‑related apoptosis‑inducing ligand induced apoptosis in T‑cell acute lymphoblastic leukemia cells via upregulation of death receptor�5
Seema Nathwani
Oncology Letters, 2016
View PDFchevron_right
High incidence of Notch-1 mutations in adult patients with T-cell acute lymphoblastic leukemia
Rosemary Gale
Leukemia, 2006
View PDFchevron_right
γ-secretase inhibitors reverse glucocorticoid resistance in T cell acute lymphoblastic leukemia
Walden Ai
Nature Medicine, 2009
View PDFchevron_right
NOTCH1/FBXW7 mutation identifies a large subgroup with favorable outcome in adult T-cell acute lymphoblastic leukemia (T-ALL): a Group for Research on Adult Acute Lymphoblastic Leukemia (GRAALL) study
marie c bene
Blood, 2008
View PDFchevron_right
γ-Secretase inhibitor I induces apoptosis in chronic lymphocytic leukemia cells by proteasome inhibition, endoplasmic reticulum stress increase and notch down-regulation
Filomena De Falco
International Journal of Cancer, 2013
View PDFchevron_right
Growth Suppression of PreT Acute Lymphoblastic Leukemia Cells by Inhibition of Notch Signaling
Yunsun Nam
Molecular and Cellular Biology, 2003
View PDFchevron_right
Notch-1 Mutations Are Secondary Events in Some Patients with T-Cell Acute Lymphoblastic Leukemia
Rosemary Gale
Clinical Cancer Research an Official Journal of the American Association For Cancer Research, 2007
View PDFchevron_right
PSEN1-selective gamma-secretase inhibition in combination with kinase or XPO-1 inhibitors effectively targets T cell acute lymphoblastic leukemia
charlien vandersmissen
2021
View PDFchevron_right
The γ-secretase inhibitors enhance the anti-leukemic activity of ibrutinib in B-CLL cells
Emmanouil Athanasakis
Oncotarget
View PDFchevron_right
Mutations in the HD and PEST domain of Notch-1 receptor in T-cell acute lymphoblastic leukemia: report of novel mutations from Indian population
Aparna Bhanushali
Oncology research, 2010
View PDFchevron_right
CDK6-mediated repression of CD25 is required for induction and maintenance of Notch1-induced T-cell acute lymphoblastic leukemia
Nelson Brown
Leukemia, 2015
View PDFchevron_right
Inv(11)(q21q23) fuses MLL to the Notch co-activator mastermind-like 2 in secondary T-cell acute lymphoblastic leukemia
M. Staege , Rolf Marschalek
Leukemia, 2008
View PDFchevron_right
Impact of NOTCH1/FBXW7 mutations on outcome in pediatric T-cell acute lymphoblastic leukemia patients treated on the MRC UKALL 2003 trial
Rosemary Gale
Leukemia, 2012
View PDFchevron_right
Activating Mutations of NOTCH1 in Human T Cell Acute Lymphoblastic Leukemia
Jon Aster
Science, 2004
View PDFchevron_right
The Challenge of Targeting Notch in Hematologic Malignancies
Fiorela Hernández
Frontiers in Pediatrics, 2014
View PDFchevron_right